Home » Stocks » MRSN

Mersana Therapeutics, Inc. (MRSN)

Stock Price: $21.22 USD -0.45 (-2.08%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $21.18 -0.04 (-0.19%) Jan 20, 7:48 PM
Market Cap 1.49B
Revenue (ttm) 860,000
Net Income (ttm) -75.45M
Shares Out 68.42M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $21.22
Previous Close $21.67
Change ($) -0.45
Change (%) -2.08%
Day's Open 21.83
Day's Range 21.16 - 21.96
Day's Volume 893,670
52-Week Range 4.41 - 27.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of an...

Benzinga - 4 days ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: CAG, ALDX, DMTK, FATE, GBIO, ORI, REVG, RILY, SPT, YORW
Seeking Alpha - 1 week ago

Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates ("ADCs") for cancer patients. Mersana has developed an early-stage pipeline of 8 therapeu...

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

The Motley Fool - 2 weeks ago

The company reported disappointing clinical results.

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

Zacks Investment Research - 3 weeks ago

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: FATE, MRNA, NTLA, RARE
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

The Motley Fool - 1 month ago

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, FPRX, SURF, TRIL
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of an...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

Seeking Alpha - 2 months ago

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

- Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET - - Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET -

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ant...

GlobeNewsWire - 4 months ago

- Maintained 34% objective response rate and 79% disease control rate, including two complete responses 

Investopedia - 4 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, NVAX, REGN, TECH, VNDA, XBIT
Seeking Alpha - 4 months ago

Mersana Therapeutics: Poised To Capitalize As Billions Pour Into ADCs

GlobeNewsWire - 4 months ago

- Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET -

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Seeking Alpha - 5 months ago

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

 - Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease contro...

Benzinga - 5 months ago

Mersana Therapeutics (NASDAQ: MRSN) releases its next round of earnings this Friday, August 07.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of a...

Zacks Investment Research - 6 months ago

Here we pick five Nasdaq-listed momentum stocks that are well-poised to grow on solid prospects in the remainder of 2020.

Other stocks mentioned: BZUN, EVBG, OKTA, ZM
Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of a...

The Motley Fool - 7 months ago

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: AGIO, JNCE, STRO
Zacks Investment Research - 7 months ago

Mersana Therapeutics (MRSN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research - 7 months ago

Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener

Other stocks mentioned: BGS, CODX
GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of a...

Zacks Investment Research - 7 months ago

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Other stocks mentioned: ALRN, CBAY, EFOI, MVIS
Zacks Investment Research - 7 months ago

Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of an...

Zacks Investment Research - 7 months ago

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

Zacks Investment Research - 7 months ago

Mersana Therapeutics (MRSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of an...

Zacks Investment Research - 7 months ago

Shares of biotech firm Mersana Therapeutics (MRSN) soared on Wednesday, closing up 69% to $18.19 per share. What was the cause

Benzinga - 7 months ago

Mersana Therapeutics (NASDAQ: MRSN) shares are trading higher on Wednesday. The company reported interim safety, tolerability and efficacy data from the ongoing expansion portion of its Phase ...

The Motley Fool - 7 months ago

Investors are excited about the biotech's encouraging results from an early-stage clinical trial.

24/7 Wall Street - 7 months ago

Mersana Therapeutics Inc. (NASDAQ: MRSN) shares jumped on Wednesday after the company reported interim results from its early-stage cancer study.

GlobeNewsWire - 7 months ago

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 20th

Other stocks mentioned: AAWW, IDCC
InvestorPlace - 8 months ago

These 10 up-and-coming stocks are among some of the best hyper-growth stocks investors should buy for the next decade of gains.

Other stocks mentioned: BYND, CDLX, CHGG, NIO, OKTA, PINS, PLUG, SPCE, TTD
GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of an...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of an...

About MRSN

Mersana Therapeutics, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non smal... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2017
CEO
Nicholas Bacopoulos
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
MRSN
Full Company Profile

Financial Performance

In 2019, MRSN's revenue was $42.12 million, an increase of 297.61% compared to the previous year's $10.59 million. Losses were -$28.21 million, -56.10% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for MRSN stock is "Strong Buy." The 12-month stock price forecast is 33.00, which is an increase of 55.51% from the latest price.

Price Target
$33.00
(55.51% upside)
Analyst Consensus: Strong Buy